GranuFlo and NaturaLyte are two dialysates manufactured by Fresenius and used in Fresenius’s dialysis clinics, as well as in other dialysis centers and hospitals throughout Missouri and the United States. In recent months, the U.S. Food and Drug Administration (FDA) has launched an investigation into what Fresnius may have known about the risks of using GranuFlo or NaturaLyte – but did not tell its patients. Experienced Missouri GranuFlo injury attorneys have followed the situation to ensure they can provide solid representation to their clients.
Risks related to the use of either dialysate include heart attack, low blood pressure, low blood oxygen, and other conditions that can cause serious injury or death. These risks are particularly high for dialysis patients who also take bicarbonates in addition to undergoing dialysis. The risk is increased for these patients because GranuFlo and NaturaLyte contain high levels of substances that turn to bicarbonate in the blood. Patients who take bicarbonates in addition to receiving dialysis with GranuFlo or NaturaLyte, then, are at a higher risk of a bicarbonate overdose.